ENHERTU® demonstrated highly statistically significant and clinically meaningful improvement in invasive disease-free survival vs. T-DM1 in DESTINY-Breast05 Phase III trial
ENHERTU® demonstrated highly statistically significant and clinically meaningful improvement in invasive disease-free survival vs. T-DM1 in DESTINY-Breast05 Phase III trial
AstraZeneca launches direct-to-consumer platform to expand access to medications for US patients, including those living with chronic conditions
ENHERTU® plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer
SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer
AIRSUPRA® US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma compared with albuterol
SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis
Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock
UPDATE - Critical Metals Corp (NASDAQ: CRML) Secures Another Significant Tanbreez Offtake Agreement for 15% of its Production with Leading U.S. Vertically Integrated Rare Earth Company, REalloys Inc.
